Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Assets Average (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Assets Average for 10 consecutive years, with $641.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 24.56% year-over-year to $641.2 million, compared with a TTM value of $641.2 million through Dec 2025, up 24.56%, and an annual FY2025 reading of $693.1 million, up 45.87% over the prior year.
  • Assets Average was $641.2 million for Q4 2025 at Spyre Therapeutics, up from $521.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $641.2 million in Q4 2025 and bottomed at $61.8 million in Q1 2023.
  • Average Assets Average over 5 years is $289.2 million, with a median of $194.0 million recorded in 2021.
  • The sharpest move saw Assets Average tumbled 40.63% in 2022, then skyrocketed 571.1% in 2024.
  • Year by year, Assets Average stood at $119.5 million in 2021, then tumbled by 31.92% to $81.4 million in 2022, then soared by 237.49% to $274.6 million in 2023, then skyrocketed by 87.49% to $514.8 million in 2024, then increased by 24.56% to $641.2 million in 2025.
  • Business Quant data shows Assets Average for SYRE at $641.2 million in Q4 2025, $521.7 million in Q3 2025, and $554.3 million in Q2 2025.